Simple Summary In recent decades, neoadjuvant chemotherapy has proven to be a viable
therapeutic option, particularly in cases of high-risk early or locally advanced breast cancer …

The use of immune checkpoint inhibitors (ICIs) has increased exponentially in the past
decade, although its progress specifically for breast cancer has been modest. The first US …

Immune checkpoint inhibition combined with chemotherapy is currently approved as first-
line treatment for patients with advanced PD-L1–positive triple-negative breast cancer …

Breast cancer (BC) is the most common neoplasm in women worldwide and one of the
leading causes of female death. The triple-negative subtype, characterized by the absence …

Background Toliparibizumab in combination with nab-paclitaxel (T+ N) has excellent
efficacy inmetastatic or recurrent triple-negative breast cancer (TNBC), but the optimal …

Triple-negative breast cancer (TNBC) poses significant challenges in oncology due to its
aggressive nature, limited treatment options, and poorer prognosis compared to other breast …

Triple-negative breast cancer (TNBC) is a highly heterogeneous breast cancer subtype,
which is also characterized by the aggressive phenotype, high recurrence rate, and poor …

Breast cancer (BC) is the most commonly diagnosed cancer in women worldwide and the
second largest cause of cancer-related deaths. Recently, numerous agents, including …

The implementation of adjuvant antitumor drug therapy, covering all patients who are
prescribed this type of treatment according to a set of formal group criteria, provides a benefit …